RO8994 - CAS# 1309684-94-3 xrazoxane InChi: InChI=1S/C21H21N3O2/c1-3-17-18(13-4-6-15(7-5-13)21(26)23-2)12-24-20(22)19(17)14-8-10-16(25)11-9-14/h4-12

InChi: InChI=1S/C21H21N3O2/c1-3-17-18(13-4-6-15(7-5-13)21(26)23-2)12-24-20(22)19(17)14-8-10-16(25)11-9-14/h4-12

Formula: C21H20N2O3

An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity

Chemical Name: (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide

RO8994 - CAS# 1309684-94-3 xrazoxane InChi: InChI=1S/C21H21N3O2/c1-3-17-18(13-4-6-15(7-5-13)21(26)23-2)12-24-20(22)19(17)14-8-10-16(25)11-9-14/h4-12RO8994 is a highly potent and selective series of spiroindolinone small molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). IC50 value: 5 nM (in HTRF binding assays), 20 nM (in MTT proliferation assays) Target: MDM2 in vitro: RO8994 represents a new generation of p53 MDM2 antagonists with marked improvement in pharmacological properties for potential clinical development. RO8994 induces dose dependent